R(+) and S(-) Pramipexole Composition for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease using pramipexole face challenges due to adverse side effects from excessive dopaminergic agonism, limiting the dosage and effectiveness of S(−) pramipexole, while R(+) pramipexole's neuroprotective benefits are hindered by its low affinity for dopamine receptors and high required purity for safe administration.
Innovation Solution
Development of multicomponent pharmaceutical compositions comprising both R(+) and S(−) pramipexole with high chiral purity, in immediate or sustained release formulations, to exploit their additive neuroprotective effects and reduce adverse side effects by varying release rates and dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of S(−) pramipexole are administered to treat Parkinson's disease, then dopaminergic agonism is enhanced, but adverse side effects increase
Solution Approach 1:
The patent extracts and separates the harmful S(−) enantiomer from the therapeutic R(+) enantiomer through chiral resolution, obtaining enantiomerically pure R(+) pramipexole that provides neuroprotection without the adverse dopaminergic side effects caused by the S(−) form
Solution Approach 2:
The patent changes the chiral purity parameter from racemic mixture to enantiomerically pure R(+) pramipexole (≥99% purity), fundamentally altering the pharmacological profile to eliminate harmful dopaminergic agonism while preserving neuroprotective benefits
2Reliability
If R(+) pramipexole is used to provide neuroprotection, then mitochondrial function is enhanced, but the required high chiral purity increases manufacturing complexity
Solution Approach 1:
The patent employs preliminary chiral resolution during the synthesis process to establish high enantiomeric purity (≥99%) before formulation, ensuring the neuroprotective activity is achieved without requiring complex purification steps during later stages
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining R(+) pramipexole with specific excipients and delivery systems that facilitate the achievement and maintenance of high chiral purity while simplifying the overall manufacturing process
3Reliability
If multicomponent formulations with different release rates are developed, then additive neuroprotective effects are achieved, but formulation complexity increases
Solution Approach 1:
The patent segments the pramipexole formulation into multiple components with different release characteristics (immediate release and sustained release matrices), allowing independent optimization of each component's neuroprotective contribution while managing overall complexity through modular design
Solution Approach 2:
The patent merges R(+) pramipexole with specific excipients and delivery matrices to create multi-component formulations that achieve additive neuroprotective effects, combining the benefits of high chiral purity with optimized release profiles in a unified pharmaceutical composition
Data Source
AI summary
Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.